Immunovative Therapies initiates Phase IIb study of cancer vaccine to treat metastatic colorectal cancer

Immunovative Therapies' subsidiary ImmunoCare has reported the start of a Phase IIb study of CryoVax, a next-generation immunotherapy cancer vaccine product for patients with chemotherapy-refractory (third line) metastatic colorectal cancer (mCRC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news